Advertisement

Advertisement
Kyle F. Concannon, MD, on Lung Cancer in Homeless Patients: Outcomes and Quality Measures

Kyle F. Concannon, MD, on Lung Cancer in Homeless Patients: Outcomes and Quality Measures

Studies Find Trilaciclib May Improve Chemotherapy Experience for Patients With Small Cell Lung Cancer

Studies Find Trilaciclib May Improve Chemotherapy Experience for Patients With Small Cell Lung Cancer

In patients with extensive-stage small cell lung cancer (SCLC), adding trilaciclib to standard-of-care chemotherapy demonstrated meaningful delays...

Maintenance Bevacizumab, Pemetrexed, or Both in Advanced Nonsquamous NSCLC

In the phase III ECOG-ACRIN 5508 trial, reported in the Journal of Clinical Oncology by Ramalingam et al, maintenance pemetrexed or bevacizumab was associated with no significant improvement in overall survival vs the bevacizumab control group alone, and ...

Addition of Cediranib to Cisplatin/Pemetrexed in Chemotherapy-Naive Unresectable Malignant Pleural Mesothelioma

In the phase II SWOG S0905 trial reported in the Journal of Clinical Oncology, Tsao et al found that the addition of the epidermal growth factor receptor and platelet-derived growth factor receptor inhibitor cediranib to cisplatin/pemetrexed was...

Five-Year Survival in Heavily Pretreated Patients Receiving Nivolumab Monotherapy

As reported by Topalian et al in JAMA Oncology, long-term follow up of patients from a phase I expansion cohort study indicated 5-year overall survival rates of 34.2%, 27.7%, and 15.6% among patients who received nivolumab monotherapy for advanced...

Two Investigational Agents Demonstrate Safety, Efficacy in Lung Cancer

Two Investigational Agents Demonstrate Safety, Efficacy in Lung Cancer

A handful of investigational drugs in early-phase trials always create a buzz at ASCO Annual Meetings. Two that garnered attention this year, and could eventually change outcomes in the clinic...

Advertisement


Advertisement